Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209241 · ClinicalTrials.gov registry record · Phase 1
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
A Phase 1 study of Recurrent Glioblastoma, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07209241: Recruiting Phase 1 study of Recurrent Glioblastoma, sponsored by University of Pennsylvania.
NCT07209241 is a Phase 1 study of Recurrent Glioblastoma that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 12 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07209241, a Phase 1 study of Recurrent Glioblastoma, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Primary Outcome
Type, frequency, severity, and attribution of adverse events
Conditions Studied
Interventions
- BIOLOGICAL CART-EGFR-IL13Ra2 T cells
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2042-11-01 |
| Phase | Phase 1 |
What NCT07209241 shows while recruiting
NCT07209241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which CART-EGFR-IL13Ra2 T cells is the first listed.
NCT07209241 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07209241 about?
NCT07209241 is a clinical study titled "Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM". This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior r...
What is the current status of trial NCT07209241?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-12-03. Estimated completion is 2042-11-01.
What conditions does trial NCT07209241 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT07209241?
The interventions under investigation include: CART-EGFR-IL13Ra2 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07209241?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07209241 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07209241's enrollment target sits among peer trials
12 56th of 62 higher than 6 of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
-
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI